DaVita, Inc. Stock Plummets to New 52-Week Low of $123.15

DaVita, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 123.15 on October 10, 2025. This decline marks a significant downturn for the company, which has experienced a 12.42% decrease in its stock price over the past year, contrasting sharply with the S&P 500's performance of 13.36% during the same period.
The company's market capitalization stands at USD 10,660 million, with a price-to-earnings (P/E) ratio of 10.00. However, DaVita's financial metrics reveal underlying concerns, including a negative book value and a return on equity of -296.97%. The company has also reported a debt-to-equity ratio of -26.14, indicating a high level of debt relative to its equity.

Despite a modest annual operating profit growth rate of 2.01% over the last five years, DaVita's performance has been below par both in the long term and near term. The stock's trajectory reflects a challenging environment, as it has generated a return of -20.03% over the past year, further emphasizing the difficulties faced by the company in the current market landscape.